Followers

Friday, 14 November 2014

MUST KNOW!!!! Heart cancer as we never heard of it..




The Reason We Don’t Get Heart Cancer As you likely know, we receive half our genes from our mothers, half from our fathers. While it would seem our genetic fate is sealed, “nothing could be further from the truth,” said Gaynor, whose new book on the subject, The Gene Therapy Plan, will be available in 2015. “We understand now how gene expression can be modified throughout your life… and that can create cancer,” he said. In fact, our environment affects which genes become expressed (activated) as well as how frequently they become activated. And carcinogens coming from our food and environment are one of the many factors that influence which genes are activated or not. “A lot of toxins are found in breast tissue, because there are a lot of fat cells there,” Gaynor explained. “And toxins are found wherever there is the most fat.”


 While our bodies have some defenses against these contaminants, in the form of detoxifying enzymes, and while our bodies are supported by micronutrients which turn on tumor suppressor genes, dangerous toxins found in our fat tissue still modify our genes, which can result in cancers forming in the organs of our bodies, especially those containing fatty tissue. 

This, then, is why the heart is so exceptional: “There’s not a lot of fatty tissue [in the heart],” Gaynor said. Even more, “the heart’s enclosed in a membrane,” he explained. Known as the pericardium, this fluid-filled sac may itself become engulfed by cancer, with tumors metastasizing to the outside of it, but still it does its job of protecting our precious hearts. So, even though cancer can happen anywhere there are cells, your heart remains virtually immune due to its muscular nature and the assistance of the pericardium. Smart heart.



Read more at: http://forum.facmedicine.com/threads/why-do-we-never-hear-about-heart-cancer.19966/

Saturday, 1 November 2014

Vaccination.

video




Measles is one of the most contagious of the vaccine-preventable diseases, with reproduction rates (R 0) estimated at 12 to 18 — meaning that the average person with measles would be capable of infecting 12 to 18 other people if all his or her contacts were susceptible. The herd-immunity threshold (the population immunity level needed to interrupt transmission) is usually calculated as (R 0−1)÷R 0; for measles, this threshold is on the order of 92 to 94% to prevent sustained spread of the virus — higher than the thresholds for almost all other vaccine-preventable diseases.




From statistic of the measles prevalence in US, the resurgent of the case is somewhat closely related to the increasing number of parents in this country which are hesitant to have their children vaccinated, and such hesitancy has resulted in an accumulation of unvaccinated populations who can become infected and maintain transmission.

The licensure of the first live attenuated measles vaccine in 1963 offered the opportunity to prevent this health burden. Current vaccines are highly effective — about 94% for a single dose, if it's administered in the second year of life. With two doses administered on or after the first birthday and at least 1 month apart, almost all immunocompetent children are protected against measles for life. But vaccines don't save lives — vaccinations do. Vaccines that remain in the vial are completely ineffective.


To prevent measles from being reestablished as an endemic disease in the United States, we must first do better in vaccinating our at-risk population. That means ensuring that vaccine is accessible to all who need it — especially to people traveling outside the Western Hemisphere and those traveling to the United States from countries with circulating disease — and convincing hesitant families both that the vaccine is safe and effective and that measles is not trivial and can result in serious illness.



Taken from article entitles:

Mounting a Good Offense against Measles

Walter Orenstein, M.D., and Katherine Seib, M.S.P.H.
N Engl J Med 2014; 371:1661-1663October 30, 2014DOI: 10.1056/NEJMp1408696